Larvol Delta - Combination-of-Durvalumab-and-BVACC-in-Patients-With-HPV-16-or-18-Positive-Cervical-Cancer-Failure-to-FirstLine-Platinumbased-Chemotherapy

Imfinzi (durvalumab) - AstraZeneca

BVAC-C - Cellid

http://clinicaltrials.gov/ct2/show/NCT04800978

Mar 16, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next